Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF.
Studies in mouse infection models clearly demonstrate tumour necrosis factor (TNF) to be a critical component of both the antibacterially protective and the inflammatory immune response to Mycobacterium tuberculosis. It is therefore not surprising that treatment of patients-for example, those with rheumatoid arthritis-with biological agents interfering with TNF activity have shown an increased risk of reactivating tuberculosis. However, conceivably, TNF targeting biological agents can be developed that because of their particular mode of action and their specific pharmacodynamics may be less likely to have this side effect.
Ehlers
S
S
Molecular Infection Biology, Research Centre Borstel, D-23845 Borstel, Germany. sehlers@fz-borstel.de
D000818:Animals; D007155:Immunologic Factors / Q000009:adverse effects*; D008233:Lymphotoxin-alpha / Q000276:immunology; D051379:Mice; D009894:Opportunistic Infections / Q000139:chemically induced; D012008:Recurrence; D018570:Risk Assessment; D014376:Tuberculosis / Q000139:chemically induced / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
D007155:Immunologic Factors; D008233:Lymphotoxin-alpha; D014409:Tumor Necrosis Factor-alpha